Vonjo (pacritinib) is a prescription medication for patients with specific types of myelofibrosis. Its purchase and use must strictly comply with medical regulations.

How to Purchase Vonjo (Pacritinib)

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or legitimate drugstores in countries or regions where Vonjo has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchasing Vonjo (Pacritinib)

Bleeding Risk Assessment

Avoid use in patients with active bleeding.

Discontinue the medication 7 days before any planned surgery or invasive procedure.

Resume medication only after confirmed hemostasis.

Cardiovascular System Assessment

Avoid use in patients with a baseline QTc interval > 480 milliseconds.

Correct hypokalemia before and during medication use.

The risk of major adverse cardiac events may be increased in current or former smokers and patients with other cardiovascular risk factors.

Contraindications

Patients concurrently using strong CYP3A4 inhibitors or inducers.

Patients with severe renal impairment (eGFR < 30 mL/min).

Patients with a history of allergy to pacritinib or any of its components.

Prohibited Concurrent Use

Strong CYP3A4 inhibitors (e.g., clarithromycin).

Strong CYP3A4 inducers (e.g., rifampicin).

Requiring Close Monitoring

When used concurrently with moderate CYP3A4 inhibitors.

When used concurrently with CYP1A2 substrates, CYP3A4 substrates, or P-gp substrates.

Methods to Identify the Authenticity of Vonjo (Pacritinib)

Packaging and Capsule Characteristics

Product name: VONJO (Pacritinib) Capsules.

Drug specification: 100 mg.

NDC code: 72482-100-12.

Capsule Appearance Identification

Hard, oval-shaped, opaque gelatin capsules.

Dark red cap and gray body.

The cap is imprinted with "Pacritinib 100mg".

The body is imprinted with "C78837".